Swiss Drug Giant Roche Had 42% of Its 2016 Total Revenues Made To US Customers and 34% of Its 2016 Total Property, Plant and Equipment, the Main Drivers of the Coveted US Deferred Income Tax Liabilities (DTLs), Located in the US

From Roche's 2016 Financial Report